Shedding light on ocular findings in COVID-19 patients
May 14, 2021
According to investigators, understanding the ocular manifestations in patients with COVID-19 could ultimately help with the diagnosis and prevent transmission.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
All News
Results unveiled from phase 2/3 gene therapy study for XLRP
May 14, 2021
While Biogen’s XIRIUS study did not meet its primary endpoint of demonstrating a statistically significant improvement in treated eyes, positive trends were observed across several clinically relevant prespecified secondary endpoints.
Minimally invasive retinal reattachment procedure leads to enhanced photoreceptor integrity
May 13, 2021
A study led by investigators at St. Michael's Hospital of Unity Health Toronto supports pneumatic retinopexy as a primary retinal reattachment technique to achieve better long-term integrity of photoreceptors.
Enrollment completed in VEGA-1 Phase 2 clinical trial for presbyopia treatment
May 12, 2021
Ocuphire Pharma has completed enrollment in the VEGA-1 Phase 2 clinical trial evaluating the safety and efficacy of drops to treat presbyopia.
Investigators develop technique to assess progression of sickle cell retinopathy
May 11, 2021
Ophthalmologists at New York Eye and Ear Infirmary of Mount Sinai have created a new technique to evaluate patients with sickle cell retinopathy and assess the disease before it progresses and leads to permanent vision loss.
HHS to enforce prohibition of sex discrimination on basis of sexual orientation, gender identity
May 11, 2021
In an announcement that could impact ophthalmologists, the Department of Health and Human Services’ Office for Civil Rights revealed this week that it will enforce a prohibition of discrimination on the basis of sexual orientation and gender identity.
Oculis announces positive data from phase 2 trials with novel topical TNF alpha antagonist OCS-02 for DED, acute anterior uveitis
May 11, 2021
Oculis reported positive data from two of its clinical proof-of-concept phase 2 trials for OCS-02, a novel topical anti-TNF alpha antibody fragment candidate, for the treatment of dry eye disease and acute anterior uveitis.
Preliminary topline results from Phase 2b ALTISSIMO trial unveiled
May 10, 2021
Graybug Vision’s Phase 2b ALTISSIMO trial of GB-102 focuses on the treatment of wet age-related macular degeneration.
Reducing post-cataract surgery endophthalmitis: Investigators focus on therapeutic regimen
May 10, 2021
Findings from retrospective study support intraoperative cefuroxime irrigation.
Repository corticotropin injections: Relief for refractory severe noninfectious keratitis
May 07, 2021
Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.